Browse the corpus

REFERENCES Baddour LM, Wilson WR, Bayer AS, et al, “Infective Endocarditis. Diagnosis, Antimicrobial Therapy, and Management of Complications: A Statement for Healthcare Professionals From the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association - Executive Summary: Endorsed by the Infectious Diseases Society of America ,” Circulation , 2005, 111(23):3167-184. [PubMed 15956145 ] Blackwell BG, Leggett JE, Johnson CA, et al, “Ampicillin and Sulbactam Pharmacokinetics and Pharmacodynamics in Continuous Ambulatory Peritoneal Dialysis (CAPD),” Perit Dial Int , 1990, 10(3):221-6. [PubMed 2099158 ] Blum RA, Kohli RK, Harrison NJ, et al, “Pharmacokinetics of Ampicillin (2.0 Grams) and Sulbactam (1.0 Gram) Coadministered to Subjects With Normal and Abnormal Renal Function and With End-Stage Renal Disease on Hemodialysis,” Antimicrob Agents Chemother , 1989, 33(9):1470-6. [PubMed 2817847 ] Bratzler DW, Dellinger EP, Olsen KM, et al, “Clinical Practice Guidelines for Antimicrobial Prophylaxis in Surgery,” Am J Health Syst Pharm , 2013, 70(3):195-283. [PubMed 23327981 ] Centers for Disease Control and Prevention (CDC), "Sexually Transmitted Diseases Treatment Guidelines, 2010," MMWR Recomm Rep , 2010, 59(RR-12):1-110. [PubMed 21160459 ] Chow AW, Benninger MS, Brook I, et al, “IDSA Clinical Practice Guideline for Acute Bacterial Rhinosinusitis in Children and Adults,” Clin Infect Dis , 2012, 54(8):e72-112. [PubMed 22438350 ] Chow MS, Quintiliani R, and Nightingale CH, “ In Vivo Inactivation of Tobramycin by Ticarcillin. A Case Report,” JAMA , 1982, 247(5):658-9. [PubMed 6798229 ] Dajani AS, “Sulbactam/Ampicillin in Pediatric Infections,” Drugs , 1988, 35(Suppl 7):35-8. Daly JS, Dodge RA, Glew RH, et al, “Effect of Time and Temperature on Inactivation of Aminoglycosides by Ampicillin at Neonatal Dosages," J Perinatol , 1997, 17(1):42-5. [PubMed 9069064 ] Donowitz GR and Mandell GL, “Beta-Lactam Antibiotics,” N Engl J Med , 1988, 318(7):419-26 and 318(8):490-500. [PubMed 3277054 ]

Dajani AS, “Sulbactam/Ampicillin in Pediatric Infections,” Drugs , 1988, 35(Suppl 7):35-8. Daly JS, Dodge RA, Glew RH, et al, “Effect of Time and Temperature on Inactivation of Aminoglycosides by Ampicillin at Neonatal Dosages," J Perinatol , 1997, 17(1):42-5. [PubMed 9069064 ] Donowitz GR and Mandell GL, “Beta-Lactam Antibiotics,” N Engl J Med , 1988, 318(7):419-26 and 318(8):490-500. [PubMed 3277054 ] Dowell JA, Korth-Bradley J, Milisci M, et al, “Evaluating Possible Pharmacokinetic Interactions Between Tobramycin, Piperacillin, and a Combination of Piperacillin and Tazobactam in Patients With Various Degrees of Renal Impairment,” J Clin Pharmacol , 2001, 41:979-86. [PubMed 11549103 ] Farchione LA, “Inactivation of Aminoglycosides by Penicillins,” J Antimicrob Chemother , 1982, 8(Suppl A):27-36. Fuchs PC, Stickel S, Anderson PH, et al, “ In Vitro Inactivation of Aminoglycosides by Sulbactam, Other Beta-Lactams, and Sulbactam-Beta-Lactam Combinations,” Antimicrob Agents Chemother , 1991, 35(1):182-4. [PubMed 2014975 ] Goldfarb J, Aronoff SC, Jaffé A, et al, “Sultamicillin in the Treatment of Superficial Skin and Soft Tissue Infections in Children,” Antimicrob Agents Chemother , 1987, 31(4):663-4. [PubMed 3038003 ] Halstenson CE, Wong MO, Herman CS, et al, “Effect of Concomitant Administration of Piperacillin on the Dispositions on Isepamicin and Gentamicin in Patients With End-Stage Renal Disease,” Antimicrob Agents Chemother , 1992, 36(9):1832-36. [PubMed 1416875 ] Heintz BH, Matzke GR, Dager WE, “Antimicrobial Dosing Concepts and Recommendations for Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy or Intermittent Hemodialysis,” Pharmacotherapy , 2009, 29(5):562-77. [PubMed 19397464 ] Hitt CM, Patel KB, Nicolau DP, et al, “Influence of Piperacillin-Tazobactam on Pharmacokinetics of Gentamicin Given Once Daily,” Am J Health Syst Pharm , 1997, 54(23):2704-8. [PubMed 9408514 ] Itokazu GS and Danziger LH, “Ampicillin-Sulbactam and Ticarcillin-Clavulanic Acid: A Comparison of Their In Vitro Activity and Review of Their Clinical Efficacy,” Pharmacotherapy , 1991, 11(5):382-414. [PubMed 1745624 ] Konishi H, Goto M, Nakamoto Y, et al, “Tobramycin Inactivation by Carbenicillin, Ticarcillin, and Piperacillin,” Antimicrob Agents Chemother , 1983, 23(5):653-57. [PubMed 6223576 ]

Itokazu GS and Danziger LH, “Ampicillin-Sulbactam and Ticarcillin-Clavulanic Acid: A Comparison of Their In Vitro Activity and Review of Their Clinical Efficacy,” Pharmacotherapy , 1991, 11(5):382-414. [PubMed 1745624 ] Konishi H, Goto M, Nakamoto Y, et al, “Tobramycin Inactivation by Carbenicillin, Ticarcillin, and Piperacillin,” Antimicrob Agents Chemother , 1983, 23(5):653-57. [PubMed 6223576 ] Kulhanjian J, Dunphy MG, Hamstra S, et al, “Randomized Comparative Study of Ampicillin/Sulbactam vs Ceftriaxone for Treatment of Soft Tissue and Skeletal Infections in Children,” Pediatr Infect Dis J , 1989, 8(9):605-10. [PubMed 2677956 ] Lau A, Lee M, Flascha S, et al, “Effect of Piperacillin on Tobramycin Pharmacokinetics in Patients With Normal Renal Function,” Antimicrob Agents Chemother , 1983, 24(4):533-37. [PubMed 6651279 ] Li PK, Szeto CC, Piraino B, et al, "Peritoneal Dialysis-Related Infections Recommendations: 2010 Update," Perit Dial Int , 2010, 30(4):393-423 [PubMed 20628102 ] Lipsky BA, Berendt AR, Cornia PB, et al, "2012 Infectious Diseases Society of America Clinical Practice Guideline for the Diagnosis and Treatment of Diabetic Foot Infections," Clin Infect Dis , 2012, 54(12):e132-73. [PubMed 22619242 ] Mermel LA, Allon M, Bouza E, et al, “Clinical Practice Guidelines for the Diagnosis and Management of Intravascular Catheter-Related Infection: 2009 Update by the Infectious Diseases Society of America,” Clin Infect Dis , 2009, 49(1):1-45. [PubMed 19489710 ] Meyers BR, Wilkinson P, Mendelson MH, et al, “Pharmacokinetics of Ampicillin-Sulbactam in Healthy Elderly and Young Volunteers,” Antimicrob Agents Chemother , 1991, 35(10):2098-101. [PubMed 1759832 ] Oehler RL, Velez AP, Mizrachi M, et al, “Bite-Related and Septic Syndromes Caused by Cats and Dogs,” Lancet Inf Dis , 2009, 9(7):439-47. [PubMed 19555903 ] Rafailidis PI, Ioannidou EN, and Falagas ME, “Ampicillin/Sulbactam: Current Status in Severe Bacterial Infections,” Drugs , 2007, 67(13):1829-49. [PubMed 17722953 ] Rho SP, Jones A, Woo M, et al, “Single Dose Pharmacokinetics of Intravenous Ampicillin Plus Sulbactam in Healthy Elderly and Young Subjects,” J Antimicrob Chemother , 1989, 24(4):573-80. [PubMed 2613605 ]

Rafailidis PI, Ioannidou EN, and Falagas ME, “Ampicillin/Sulbactam: Current Status in Severe Bacterial Infections,” Drugs , 2007, 67(13):1829-49. [PubMed 17722953 ] Rho SP, Jones A, Woo M, et al, “Single Dose Pharmacokinetics of Intravenous Ampicillin Plus Sulbactam in Healthy Elderly and Young Subjects,” J Antimicrob Chemother , 1989, 24(4):573-80. [PubMed 2613605 ] Russoe ME and Atkins-Thor E, “Gentamicin and Ticarcillin in Subjects With End-Stage Renal Disease. Comparison of Two Assay Methods and Evaluation of Inactivation Rate," Clin Nephrol , 1981, 15(4):175-80. [PubMed 7237864 ] Solomkin JS, Mazuski JE, Bradley JS, et al, “Diagnosis and Management of Complicated Intra-Abdominal Infections in Adults and Children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of America,” Clin Infect Dis , 2010, 50(2):133-64. [PubMed 20034345 ] Stevens DL, Bisno AL, Chambers HF, et al, “Practice Guidelines for the Diagnosis and Management of Skin and Soft-Tissue Infections,” Clin Infect Dis , 2005; 41(10):1373–406. [PubMed 16231249 ] Syriopoulou V, Bitsi M, Theodoridis C, et al, “Clinical Efficacy of Sulbactam/Ampicillin in Pediatric Infections Caused by Ampicillin-Resistant or Penicillin-Resistant Organisms,” Rev Infect Dis , 1986, 8(Suppl 5):630-3. Thompson MIB, Russo ME, Saxon BJ, et al, “Gentamicin Inactivation by Piperacillin or Carbenicillin in Patients With End-Stage Renal Disease,” Antimicrob Agents Chemother , 1982, 21(2):268-73. [PubMed 6462107 ] Trotman RL, Williamson JC, Shoemaker DM, et al, “Antibiotic Dosing in Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy,” Clin Infect Dis , 2005, 41(8):1159-66. [PubMed 16163635 ] Viollier AF, Standiford HC, Drusano GL, et al, “Comparative Pharmacokinetics and Serum Bactericidal Activity of Mezlocillin, Ticarcillin, and Piperacillin, With and Without Gentamicin,” J Antimicrob Chemother , 1985, 15(5):597-606. [PubMed 4008387 ] Wald E, Reilly JS, Bluestone CD, et al, “Sulbactam/Ampicillin in the Treatment of Acute Epiglottitis in Children,” Rev Infect Dis , 1986, 8(Suppl 5):617-9. [PubMed 3026014 ] Walterspiel JN, Feldman S, Van R, et al, “Comparative Inactivation of Isepamicin, Amikacin, and Gentamicin by Nine Beta-Lactams and Two Beta-Lactamase Inhibitors, Cilastatin and Heparin,” Antimicrob Agents Chemother , 1991, 35(9):1875-8. [PubMed 1952861 ]

Wald E, Reilly JS, Bluestone CD, et al, “Sulbactam/Ampicillin in the Treatment of Acute Epiglottitis in Children,” Rev Infect Dis , 1986, 8(Suppl 5):617-9. [PubMed 3026014 ] Walterspiel JN, Feldman S, Van R, et al, “Comparative Inactivation of Isepamicin, Amikacin, and Gentamicin by Nine Beta-Lactams and Two Beta-Lactamase Inhibitors, Cilastatin and Heparin,” Antimicrob Agents Chemother , 1991, 35(9):1875-8. [PubMed 1952861 ] Wright AJ, “The Penicillins,” Mayo Clin Proc , 1999, 74(3):290-307. [PubMed 10090000 ] Wynn RL and Bergman SA, “Antibiotics and Their Use in the Treatment of Orofacial Infections, Part I and Part II,” Gen Dent , 1994, 42(5):398-402, 498-502. [PubMed 7489869 ] Topic 8745 Version 46.0 © 2013 UpToDate, Inc. All rights reserved. | Subscription and License Agreement | Release: 21.6- C21.56 Licensed to: AsanBook Dig. Med. Lib. | Support Tag: [0504-122.72.80.101-F119FB24C4-S244013.14]